Kadcyla

Chemical Nameado-trastuzumab emtansine
Dosage FormLyophilized powder (intravenous; 100mg/160mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanyGenentech, Inc.
Approval Year2013

Indication

  • For the treatment of patients who received prior therapy for metastatic disease with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
  • For the treatment of patients who developed disease recurrence during or within six months of completing adjuvant therapy with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
  • For the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
Last updated on 4/28/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kadcyla (ado-trastuzumab emtansine) Prescribing Information2013Genentech, Inc., South San Francisco, CA
Document TitleYearSource
Breast cancer, version 3.2020.2020Journal of the National Comprehensive Cancer Network
4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4).2018Annals of Oncology